Drug Type Mesenchymal stem cell therapy |
Synonyms- |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myocardial Infarction | Phase 2 | - | - | |
Ventricular Dysfunction, Left | Phase 2 | - | - |
Phase 1/2 | 65 | Autologous human mesenchymal cells (hMSCs) (200 Million Autologous Human Mesenchymal Stem Cells (hMSCs)) | qfjentsfih(tuklytutgv) = qlkgaktfet xzogslezlo (ppuupclxon, rdxabaqpsx - agyhpyhogj) View more | - | 14 Dec 2015 | ||
(200 Million Autologous Human Bone Marrow Cells (hBMCs)) | qfjentsfih(tuklytutgv) = unrmvayxan xzogslezlo (ppuupclxon, fjcafglojm - tfbvgyaqzx) View more | ||||||
Phase 1/2 | 31 | (Allo-hMSCs) | btrmiroibw(inrsjbylps) = djgonehbmb ojyuzwdwxf (frwgorpyqz, anfncaotga - grjzvijuvz) View more | - | 27 May 2015 | ||
(Auto-hMSCs) | btrmiroibw(inrsjbylps) = awagtsbycb ojyuzwdwxf (frwgorpyqz, nzwcecaqjo - iwndniuplq) View more |